A French cohort for assessing COVID-19 vaccine responses in specific populations

Impaired immunogenicity of BNT162b2 anti-SARS-CoV-2 vaccine in patients treated for solid tumors

(2021) J. Barrière et al.   ANNALS OF ONCOLOGY

Humoral Response to the Pfizer BNT162b2 Vaccine in Patients Undergoing Maintenance Hemodialysis

(2021) Ayelet Grupper et al.   Clinical Journal of the American Society of Nephrology

Antibody response to mRNA SARS-CoV-2 vaccine among kidney transplant recipients – Prospective cohort study

(2021) Benaya Rozen-Zvi et al.   CLINICAL MICROBIOLOGY AND INFECTION

Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD

(2021) Nicholas A Kennedy et al.   GUT

Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients

(2021) Brian J. Boyarsky et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study

(2021) Leticia Monin et al.   LANCET ONCOLOGY

Antibody response to mRNA SARS-CoV-2 vaccine among dialysis patients—a prospective cohort study

(2021) Timna Agur et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Poor Anti-SARS-CoV-2 Humoral and T-cell Responses After 2 Injections of mRNA Vaccine in Kidney Transplant Recipients Treated with Belatacept

(2021) Nathalie Chavarot et al.   TRANSPLANTATION

Weak anti–SARS-CoV-2 antibody response after the first injection of an mRNA COVID-19 vaccine in kidney transplant recipients

(2021) Ilies Benotmane et al.   KIDNEY INTERNATIONAL